Intensity Therapeutics Inc INTS
News
Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026
Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
